Positive Phase IIa OS data on Immuneering’s novel MEK inhibitor

Cambridge, USA-based Immuneering Corporation (Nasdaq: IMRX) late yesterday announced positive data from its ongoing Phase IIa clinical trial evaluating atebimetinib (IMM-1-104), an oral, once-daily novel MEK inhibitor, in combination with modified gemcitabine/nab-paclitaxel (mGnP) in first-line pancreatic cancer patients.

“These exceptional data demonstrate the potential of atebimetinib plus mGnP to dramatically extend the lives of patients with advanced pancreatic cancer,” said Ben Zeskind, co-founder and chief executive of Immuneering. “94% overall survival at six months is remarkable in first-line pancreatic cancer patients. Atebimetinib was designed to deliver exceptional durability and tolerability to a broad range of patients with different cancers, and it is deeply gratifying to see evidence of that playing out first in one of the most aggressive and deadly types of cancer. Our ultimate goal is to help cancer patients outlive their disease, and today’s announcement represents an important milestone on that journey,” he noted.

Despite the positive clinical data, Immuneering shares were down 13.2% at $2.06 in pre-market activity today